Citi resumes Ligand Pharma coverage with Buy rating, $387 target

July 21, 2026 5:01 AM

(Updated - July 21, 2026 5:03 AM EDT)

Citi analyst Yigal Nochomovitz resumed coverage of Ligand Pharma (NASDAQ: LGND) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found